Cover Image
市場調查報告書

全球促血紅細胞生長素市場預測:2017年∼2027年

Global Erythropoietin Market Forecast 2017-2027: Epoetin Alfa, Epoetin Beta, Darbepoetin Alfa, Biosimilars, EPO API Manufacturing

出版商 Visiongain Ltd 商品編碼 509291
出版日期 內容資訊 英文 164 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球促血紅細胞生長素市場預測:2017年∼2027年 Global Erythropoietin Market Forecast 2017-2027: Epoetin Alfa, Epoetin Beta, Darbepoetin Alfa, Biosimilars, EPO API Manufacturing
出版日期: 2017年04月28日 內容資訊: 英文 164 Pages
簡介

全球促血紅細胞生長素市場,預計從2016年的79億美元,擴大到2027年到165億美元。

本報告提供全球促血紅細胞生長素市場相關調查分析,各產品類型、用途、各國市場分析與預測,主要市場影響要素,醫藥品有效成分 (API) 製造趨勢,及主要企業簡介等系統性資訊。

第1章 調查概要

第2章 促血紅細胞生長素的簡介

  • 促血紅細胞生長素的簡介
    • 紅血球生成素Alpha
    • 紅血球生成素β
    • Darbepoetin Alfa
    • 生物相似藥
  • 促血紅細胞生長素市場:促進要素,抑制因素,及機會
    • 促進要素
    • 抑制因素
    • 機會
  • 有前途的候補藥的清單

第3章 全球促血紅細胞生長素市場

  • 全球促血紅細胞生長素市場預測
  • 市場佔有率的變化:各市場區隔
  • 全球紅血球生成素Alpha市場:銷售額預測
    • 主要產品
    • SWOT分析
  • 全球紅血球生成素β市場:銷售額預測
  • 全球Darbepoetin Alfa市場:銷售額預測
  • 全球生物相似藥β市場:銷售額預測
  • 全球促血紅細胞生長素市場,各用途:銷售額預測
    • 市場佔有率的變化:各市場區隔
    • 全球貧血症:銷售額預測
    • 全球腎臟疾病:銷售額預測
    • 全球及其他市場區隔:銷售額預測

第4章 全球原料藥/醫藥品有效成分 (API) 製造

  • 市場佔有率的變化:各市場區隔
  • 委託API製造市場預測
  • 公司內部API製造市場預測

第5章 主要國家市場

  • 全球促血紅細胞生長素市場地區分析
  • 全球促血紅細胞生長素市場:地區預測

第6章 北美的促血紅細胞生長素市場

  • 美國的促血紅細胞生長素市場預測
  • 加拿大的促血紅細胞生長素市場

第7章 歐洲的促血紅細胞生長素市場

  • 德國的促血紅細胞生長素市場
  • 法國的促血紅細胞生長素市場
  • 英國的促血紅細胞生長素市場
  • 義大利的促血紅細胞生長素市場
  • 西班牙的促血紅細胞生長素市場
  • 其他歐洲的促血紅細胞生長素市場

第8章 亞太地區的促血紅細胞生長素市場

  • 中國的促血紅細胞生長素市場
  • 日本的促血紅細胞生長素市場
  • 印度的促血紅細胞生長素市場
  • 其他亞太地區的促血紅細胞生長素市場

第9章 南美的促血紅細胞生長素市場

  • 巴西的促血紅細胞生長素市場
  • 墨西哥的促血紅細胞生長素市場
  • 其他南美國家的促血紅細胞生長素市場

第10章 中東、非洲的促血紅細胞生長素市場

  • 沙烏地阿拉伯的促血紅細胞生長素市場
  • 南非的促血紅細胞生長素市場
  • 其他中東、非洲的促血紅細胞生長素市場

第11章 促血紅細胞生長素市場上主要企業

  • Amgen, Inc.
  • Johnson & Johnson
  • F. Hoffmann-La Roche AG
  • Biocon Ltd.
  • 3SBio, Inc.
  • Pfizer, Inc.
  • Kyowa Hakko Kirin
  • LG Life Sciences Limited
  • Intas Pharmaceuticals Ltd.
  • Novartis AG

第12章 結論

  • 全球促血紅細胞生長素市場
    • 目前主要市場區隔
    • 主要地區市場
  • 全球促血紅細胞生長素市場預測

相關報告

圖表清單

目錄
Product Code: PHA0187

The global erythropoietin market is expected to grow at a CAGR of 7.8% in the first half of the forecast period and CAGR of 4.8% in the second half of the forecast period. The market is estimated at $7.9bn in 2016 and $16.5bn in 2027.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 164-page report you will receive 84 tables and 93 figures - all unavailable elsewhere.

The 164-page report provides clear detailed insight into the global erythropoietin market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

  • Global Erythropoietin Market forecasts from 2017-2027
  • Revenue forecasts of global erythropoietin market, segmented by product type:
    • Epoetin Alfa
    • Epoetin Beta
    • Darbepoetin Alfa
    • Biosimilars
    • Others

This section also discusses the leading drugs as well as SWOT analysis of each submarket.

  • Revenue forecasts of global erythropoietin market, segmented by application:
    • Anemia (Cancer and HIV Treatment)
    • Kidney Disorders (ESRD and Dialysis)
    • Others
  • Revenue forecasts of global erythropoietin API manufacturing market, segmented by contract manufacturing and in-house manufacturing
  • Erythropoietin Leading Regional Market forecasts from 2017-2027 covering North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.

image1

Forecast for each regional market is further segmented by product type, application and country:

  • US
  • Canada
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • Rest of Europe
  • China
  • Japan
  • India
  • Rest of Asia-Pacific
  • Brazil
  • Mexico
  • Rest of Latin America
  • Saudi Arabia
  • South Africa
  • Rest of Middle East and Africa

Assessment of selected leading companies that hold major market shares in the erythropoietin market:

  • Amgen
  • Johnson & Johnson
  • Roche
  • Biocon
  • 3SBio
  • Pfizer
  • Kyowa Hakko Kirin Co Ltd
  • LG Life Sciences Limited
  • Intas Pharmaceuticals Ltd
  • Novartis AG

Visiongain's study is intended for anyone requiring commercial analyses for the erythropoietin market. You find data, trends and predictions.

Table of Contents

1. Report Overview

  • 1.1 Global Erythropoietin Market Overview
  • 1.2 Overview of Findings
  • 1.3 Structure of the Report
  • 1.4 Global Erythropoietin Market Segmentation
  • 1.5 Why You Should Read This Report
  • 1.6 How This Report Delivers
  • 1.7 Key Questions Answered by This Analytical Report
  • 1.8 Who is This Report For?
  • 1.9 Methodology
  • 1.10 Associated Visiongain Reports
  • 1.11 About Visiongain

2. Introduction to Erythropoietin

  • 2.1 An Introduction to Erythropoietin
    • 2.1.1. Epoetin Alfa
    • 2.1.2. Epoetin Beta
    • 2.1.3. Darbepoetin Alfa
    • 2.1.4. Biosimilars
  • 2.2. Erythropoietin Market: Drivers, Restraints and Opportunities
    • 2.2.1.Drivers
      • 2.2.1.1.Growing incidence of renal diseases
      • 2.2.1.2. Increasing Prevalence of Caner
      • 2.2.1.3. Higher incidence of chronic and multiple diseases, especially diabetes
    • 2.2.2.Restraints
      • 2.2.2.1. Side effects of Erythropoietin
      • 2.2.2.2. Limitations of Use
    • 2.2.3. Opportunities
      • 2.2.3.1. Changing regulatory landscape and emerging healthcare reforms
  • 2.3. List of promising candidates

3. Global Erythropoietin Market 2017-2027

  • 3.1 Global Erythropoietin Market Forecast 2017-2027
  • 3.2 Changing Market Shares by Segment 2017-2027
  • 3.3 Global Epoetin Alfa Market: Sales Forecast 2017-2027
    • 3.3.1. Leading Products in the Epoetin Alfa Market
      • 3.3.1.1.EPOGEN (Amgen, Inc.)
      • 3.3.1.2.PROCRIT/EPREX (Johnson & Johnson)
    • 3.3.2. SWOT Analysis of the Epoetin Alfa Market, 2017-2027
      • 3.3.2.1. Strength
        • 3.3.2.1.1. Good reimbursement availability
      • 3.3.2.2. Weakness
        • 3.3.2.2.1. Side effects of Epoetin alfa
        • 3.3.2.2.2. Limitations of Use
      • 3.3.2.3. Opportunity
        • 3.3.2.3.1. Increasing demand to address anemia in chronic diseases
      • 3.3.2.4. Threat
        • 3.3.2.4.1. Introduction of biosimilars of the off-patented brands
  • 3.4 Global Epoetin Beta Market: Sales Forecast 2017-2027
    • 3.4.1. Leading Products in the Epoetin Beta Market
      • 3.4.1.1. Mircera (F. Hoffmann-La Roche AG)
      • 3.4.1.2.NeoRecormon (F. Hoffmann-La Roche AG)
    • 3.4.2. SWOT Analysis of the Epoetin Beta Market, 2017-2027
      • 3.4.2.1. Strength
        • 3.4.2.1.1.Leading brand Mircera launched in the U.S.
      • 3.4.2.2. Weakness
        • 3.3.2.2.1.Mircera is not a preferred brand of the Payers
      • 3.4.2.3. Opportunity
        • 3.4.2.3.1.Increased incidences of kidney failures
      • 3.4.2.4. Threat
        • 3.4.2.4.1.Availability of cost effective biosimilars
  • 3.5 Global Darbepoetin Alfa Market: Sales Forecast 2017-2027
    • 3.5.1. Leading Products in the Darbepoetin Alfa Market
      • 3.5.1.1. Aranesp (Amgen, Inc.)
    • 3.5.2. SWOT Analysis of the Darbepoetin Alfa Market, 2017-2027
      • 3.5.2.1. Strength
        • 3.5.2.1.1. Aranesp - Patent Expiry in the US
      • 3.5.2.2. Weakness
        • 3.5.2.2.1. Aranesp - Patent Expiry in Europe
      • 3.5.2.3. Opportunity
        • 3.5.2.3.1.Increased incidences of kidney failures
      • 3.5.2.4. Threat
        • 3.5.2.4.1. Availability of biosimilars
  • 3.6 Global Biosimilars Beta Market: Sales Forecast 2017-2027
    • 3.6.1. Leading Products in the Biosimilars Market
      • 3.6.1.1.Retacrit (Hospira)
      • 3.6.1.2.EPIAO (3SBio Inc.)
      • 3.6.1.3.Epoetin Alfa BS ( Japan Chemical Research Pharmaceuticals Co., Ltd.)
      • 3.6.1.4.Espogen (LG Life Sciences Ltd)
    • 3.6.2. SWOT Analysis of the Biosimilars Market, 2017-2027
      • 3.6.2.1. Strength
        • 3.6.2.1.1. Lower cost structure
      • 3.6.2.2. Weakness
        • 3.6.2.2.1.Lack of credibility in the prescribing community
      • 3.6.2.3. Opportunity
        • 3.6.2.3.1.Favourable pricing and reimbursement policies
        • 3.6.2.3.2.Driving further innovation
      • 3.6.2.4. Threat
        • 3.6.2.4.1.Evolving regulatory environment against the industry's interests
  • 3.7 Global Erythropoietin Market, by Application: Sales Forecast 2016-2027
    • 3.7.1 Changing Market Shares by Segment 2017-2027
    • 3.7.2 Global Anemia: Sales Forecast 2016-2027
    • 3.7.3 Global Kidney Disorder: Sales Forecast 2016-2027
    • 3.7.4 Global Others Segment: Sales Forecast 2016-2027

4. Global Active pharmaceutical ingredients (API) Manufacturing of Erythropoietin Market 2017-2027

  • 4.1 Changing Market Shares by Segment 2017-2027
  • 4.2.Contract API Manufacturing Market Forecast 2017-2027
  • 4.3. In-house API Manufacturing Market Forecast 2017-2027

5.Leading National Markets 2017-2027

  • 5.1.Geographical Breakdown of the World Erythropoietin Market
  • 5.2 World Erythropoietin Market: Regional Forecast 2017-2027
    • 5.2.1 How Will Regional Market Shares Change to 2027?

6.North America Erythropoietin Market 2017-2027

  • 6.1. US Erythropoietin Market Forecast 2017-2027
  • 6.2. Canada Erythropoietin Market Forecast 2017-2027

7. Europe Erythropoietin Market 2017-2027

  • 7.1. Germany Erythropoietin Market Forecast 2017-2027
  • 7.2. France Erythropoietin Market Forecast 2017-2027
  • 7.3. U.K. Erythropoietin Market Forecast 2017-2027
  • 7.4.Italy Erythropoietin Market Forecast 2017-2027
  • 7.5.Spain Erythropoietin Market Forecast 2017-2027
  • 7.6.Rest of Europe Erythropoietin Market Forecast 2017-2027

8.Asia Pacific Erythropoietin Market 2017-2027

  • 8.1. China Erythropoietin Market Forecast 2017-2027
  • 8.2. Japan Erythropoietin Market Forecast 2017-2027
  • 8.3. India Erythropoietin Market Forecast 2017-2027
  • 8.4.Rest of Asia Pacific Erythropoietin Market Forecast 2017-2027

9. Latin America Erythropoietin Market 2017-2027

  • 9.1 Brazil Erythropoietin Market Forecast 2017-2027
  • 9.2 Mexico Erythropoietin Market Forecast 2017-2027
  • 9.3 Rest of Latin America Erythropoietin Market Forecast 2017-2027

10. Middle East and Africa Erythropoietin Market 2017-2027

  • 10.1. Saudi Arabia Erythropoietin Market Forecast 2017-2027
  • 10.2. South Africa Erythropoietin Market Forecast 2017-2027
  • 10.3.Rest of Middle East and Africa Erythropoietin Market Forecast 2017-2027

11. Leading Companies in the Erythropoietin Market

  • 11.1. Amgen, Inc.
    • 11.1.1 Amgen, Inc. Corporation: Erythropoietin Product Portfolio
    • 11.1.2 Financial Overview
    • 11.1.2.Recent Transactions Summary
  • 11.2. Johnson & Johnson
    • 11.2.1. Johnson & Johnson: Erythropoietin Product Portfolio
    • 11.1.2 Financial Overview
    • 11.2.3.Recent Transactions Summary
  • 11.3. F. Hoffmann-La Roche AG
    • 11.3.1 Roche: Erythropoietin Product Portfolio
    • 11.3.2 Roche: Financial Overview
    • 11.3.3.Recent Transactions Summary
  • 11.4. Biocon Ltd.
    • 11.4.1 Biocon: Erythropoietin Product Portfolio
    • 11.4.2 Biocon: Financial Overview
    • 11.4.3 Biocon: Recent Developments
  • 11.5. 3SBio, Inc.
    • 11.5.1 3SBio: Erythropoietin Product Portfolio
    • 11.5.2 3SBio: Financial Overview
    • 11.5.3 3SBio: Recent Developments
  • 11.6. Pfizer, Inc.
    • 11.6.1 Pfizer, Inc.: Erythropoietin Product Portfolio
    • 11.6.2 Pfizer, Inc.: Financial Overview
    • 11.6.3 Pfizer, Inc.: Recent Developments
  • 11.7. Kyowa Hakko Kirin Co Ltd.
    • 11.7.1 Kyowa Hakko Kirin Co Ltd.: Erythropoietin Product Portfolio
    • 11.7.2 Kyowa Hakko Kirin Co Ltd.: Financial Overview
    • 11.7.3 Kyowa Hakko Kirin Co Ltd.: Recent Developments
  • 11.8. LG Life Sciences Limited
    • 11.8.1 LG Life Sciences Limited: Erythropoietin Product Portfolio
    • 11.8.2 LG Life Sciences Limited: Financial Overview
    • 11.8.3 LG Life Sciences Limited: Recent Developments
  • 11.9. Intas Pharmaceuticals Ltd.
    • 11.7.1 Intas Pharmaceuticals Ltd.: Erythropoietin Product Portfolio
    • 11.7.2 Intas Pharmaceuticals Ltd.: Recent Developments
  • 11.7. Novartis AG
    • 11.7.1 Novartis AG: Erythropoietin Product Portfolio
    • 11.7.2 Novartis AG: Financial Overview
    • 11.7.3 Novartis AG: Recent Developments

12. Conclusions

  • 12.1 The World Erythropoietin Market in 2016 and 2017
    • 12.1.1 Current Leading Erythropoietin Segments
    • 12.1.3 Leading Regional Markets
  • 12.2 World Erythropoietin Market Forecast 2017-2027

Associated Visiongain Reports

  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain Report Evaluation Form

List of Tables

  • Table 2.1 Top 10 countries for cancer frequency by country
  • Table 2.2 Top 10 countries for numbers of people aged 20-79 years with diabetes in 2011 and 2030
  • Table: 2.3. List of Promising Candidates Phase II
  • Table 2.4: List of Promising Candidates Phase III
  • Table 3.1 Global Erythropoietin Market by Product Type: Revenue ($m) and Market Share (%), 2016
  • Table 3.2 Global Erythropoietin Market Forecast, By Product Type: Revenues ($m), AGR (%), CAGR (%), 2015-2027
  • Table 3.3 Global Epoetin Alfa Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2015-2027
  • Table 3.4 Global EPOGEN Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2015-2027
  • Table 3.5 Global PROCRIT/EPREX Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2015-2027
  • Table 3.6 SWOT Analysis of the Epoetin Alfa Market, 2017-2027
  • Table 3.7 Global Epoetin Beta Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2015-2027
  • Table 3.8 Global Mircera Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2015-2027
  • Table 3.9 Global NeoRecormon Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2015-2027
  • Table 3.10 SWOT Analysis of the Epoetin Beta Market, 2017-2027
  • Table 3.11 Global Darbepoetin Alfa Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2015-2027
  • Table 3.12 Global Aranesp Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2015-2027
  • Table 3.13 SWOT Analysis of the Darbepoetin Alfa Market, 2017-2027
  • Table 3.14 Global Biosimilars Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2015-2027
  • Table 3.15 Global Retacrit Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2015-2027
  • Table 3.16 Global EPIAO Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2015-2027
  • Table 3.17 Global Epoetin Alfa BS Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2015-2027
  • Table 3.18 Global Espogen Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2015-2027
  • Table 3.19 SWOT Analysis of the Biosimilars Market, 2017-2027
  • Table 3.20 Global Erythropoietin Market Forecast, By Application: Revenues ($m), AGR (%), CAGR (%), 2015-2027
  • Table 3.21 Global Anemia Forecast: Revenues ($m), AGR (%), CAGR (%), 2015-2027
  • Table 3.22 Global Kidney Disorders Forecast: Revenues ($m), AGR (%), CAGR (%), 2015-2027
  • Table 3.23 Global Others: Revenues ($m), AGR (%), CAGR (%), 2015-2027
  • Table 4.1 Global Erythropoietin API Manufacturing Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2015-2027
  • Table 4.2 Global Contract Erythropoietin API Manufacturing Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2015-2027
  • Table 4.3 Global In-house Erythropoietin API Manufacturing Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2015-2027
  • Table 5.1 Global Erythropoietin Market by Region: Revenue ($m), 2015 and 2016
  • Table 5.2 World Erythropoietin Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Region, 2015-2027
  • Table 6.1 North America Erythropoietin Market Forecast, By Product Type: Revenues ($m), AGR (%), CAGR (%), 2015-2027
  • Table 6.2 North America Erythropoietin Market Forecast, By Application: Revenues ($m), AGR (%), CAGR (%), 2015-2027
  • Table 6.3 North America Erythropoietin Market Forecast, By Country, 2015-2027 ($m, AGR %, CAGR %)
  • Table 6.4 US Erythropoietin Market Forecast, By Country, 2015-2027 ($m, AGR %, CAGR %)
  • Table 6.5 Canada Erythropoietin Market Forecast, By Country, 2015-2027 ($m, AGR %, CAGR %)
  • Table 7.1 Europe Erythropoietin Market Forecast, By Product Type: Revenues ($m), AGR (%), CAGR (%), 2015-2027
  • Table 7.2 Europe Erythropoietin Market Forecast, By Application: Revenues ($m), AGR (%), CAGR (%), 2015-2027
  • Table 7.3 Europe Erythropoietin Market Forecast, By Country, 2015-2027 ($m, AGR %, CAGR %)
  • Table 7.4 Germany Erythropoietin Market Forecast, By Country, 2015-2027 ($m, AGR %, CAGR %)
  • Table 7.5 France Erythropoietin Market Forecast, By Country, 2015-2027 ($m, AGR %, CAGR %)
  • Table 7.6 U.K. Erythropoietin Market Forecast, By Country, 2015-2027 ($m, AGR %, CAGR %)
  • Table 7.7 Italy Erythropoietin Market Forecast, By Country, 2015-2027 ($m, AGR %, CAGR %)
  • Table 7.8 Spain Erythropoietin Market Forecast, By Country, 2015-2027 ($m, AGR %, CAGR %)
  • Table 7.9 Rest of Europe Erythropoietin Market Forecast, 2015-2027 ($m, AGR %, CAGR %)
  • Table 8.1 Asia Pacific Erythropoietin Market Forecast, By Product Type: Revenues ($m), AGR (%), CAGR (%), 2015-2027
  • Table 8.2 Asia Pacific Erythropoietin Market Forecast, By Application: Revenues ($m), AGR (%), CAGR (%), 2015-2027
  • Table 8.3 Asia Pacific Erythropoietin Market Forecast, By Country, 2015-2027 ($m, AGR %, CAGR %)
  • Table 8.4 China Erythropoietin Market Forecast, By Country, 2015-2027 ($m, AGR %, CAGR %)
  • Table 8.5 Japan Erythropoietin Market Forecast, By Country, 2015-2027 ($m, AGR %, CAGR %)
  • Table 8.6 India Erythropoietin Market Forecast, By Country, 2015-2027 ($m, AGR %, CAGR %)
  • Table 8.7 Rest of Asia Pacific Erythropoietin Market Forecast, By Country, 2015-2027 ($m, AGR %, CAGR %)
  • Table 9.1 Latin America Erythropoietin Market Forecast, By Product Type: Revenues ($m), AGR (%), CAGR (%), 2015-2027
  • Table 9.2 Latin America Erythropoietin Market Forecast, By Application: Revenues ($m), AGR (%), CAGR (%), 2015-2027
  • Table 9.3 Latin America Erythropoietin Market Forecast, By Country, 2015-2027 ($m, AGR %, CAGR %)
  • Table 9.4 Brazil Erythropoietin Market Forecast, By Country, 2015-2027 ($m, AGR %, CAGR %)
  • Table 9.5 Mexico Erythropoietin Market Forecast, By Country, 2015-2027 ($m, AGR %, CAGR %)
  • Table 9.6 Rest of Latin America Erythropoietin Market Forecast, By Country, 2015-2027 ($m, AGR %, CAGR %)
  • Table 10.1 Middle East and Africa Erythropoietin Market Forecast, By Product Type: Revenues ($m), AGR (%), CAGR (%), 2015-2027
  • Table 10.2 Middle East and Africa Erythropoietin Market Forecast, By Application: Revenues ($m), AGR (%), CAGR (%), 2015-2027
  • Table 10.3 Middle East and Africa Erythropoietin Market Forecast 2015-2027 ($m, AGR %, CAGR %)
  • Table 10.4 Saudi Arabia Erythropoietin Market Forecast, By Country, 2015-2027 ($m, AGR %, CAGR %)
  • Table 10.5 South Africa Erythropoietin Market Forecast, By Country, 2015-2027 ($m, AGR %, CAGR %)
  • Table 10.6 Rest of MEA Erythropoietin Market Forecast, By Country, 2015-2027 ($m, AGR %, CAGR %)
  • Table 11.1 Amgen, Inc.Corporation: Overview, 2017
  • Table 11.2 Amgen, Inc.: Revenue ($m), AGR (%), 2011-2015
  • Table 11.3.Johnson & Johnson: Overview, 2017
  • Table 11.4 Johnson & Johnson: Revenue ($m), AGR (%), 2011-2015
  • Table 11.5 Roche: Overview, 2017
  • Table 11.6 Roche: Revenue ($m), AGR (%), 2011-2015
  • Table 11.7 Biocon: Overview, 2017
  • Table 11.8 Biocon: Revenue ($m), AGR (%), 2012-2016
  • Table 11.9 3SBio: Overview, 2017
  • Table 11.10 3SBio: Revenue ($m), AGR (%), 2011-2015
  • Table 11.11 Pfizer, Inc.: Overview, 2017
  • Table 11.12 Pfizer, Inc.: Revenue ($m), AGR (%), 2011-2015
  • Table 11.13 Kyowa Hakko Kirin Co Ltd: Overview, 2017
  • Table 11.14 Kyowa Hakko Kirin Co Ltd: Revenue ($m), AGR (%), 2011-2015
  • Table 11.15 LG Life Sciences Limited: Overview, 2017
  • Table 11.16 LG Life Sciences Limited: Revenue ($m), AGR (%), 2011-2015
  • Table 11.17 Intas: Overview, 2017
  • Table 11.18 Novartis: Overview, 2017
  • Table 11.19 Novartis: Revenue ($m), AGR (%), 2012-2016

List of Figures

  • Figure 1.1 Global Erythropoietin Market Segmentation Overview
  • Figure 3.1 Global Erythropoietin Market by Product Type: Market Share (%), 2016
  • Figure 3.2 Global Erythropoietin Market Forecast: Revenue ($m), AGR (%), 2015-2027
  • Figure 3.3 Global Erythropoietin Market by Product Type: Market Share (%), 2016
  • Figure 3.4 Global Erythropoietin Market by Product Type: Market Share (%), 2021
  • Figure 3.5 Global Erythropoietin Market by Product Type: Market Share (%), 2027
  • Figure 3.6 Global Epoetin Alfa Forecast: Revenue ($m), AGR (%), 2015-2027
  • Figure 3.7 Global EPOGEN Forecast: Revenue ($m), AGR (%), 2015-2027
  • Figure 3.8 Global PROCRIT/EPREX Forecast: Revenue ($m), AGR (%), 2015-2027
  • Figure 3.9 Global Epoetin Beta Forecast: Revenue ($m), AGR (%), 2015-2027
  • Figure 3.10 Global Mircera Forecast: Revenue ($m), AGR (%), 2015-2027
  • Figure 3.11 Global NeoRecormon Forecast: Revenue ($m), AGR (%), 2015-2027
  • Figure 3.12 Global Darbepoetin Alfa Forecast: Revenue ($m), AGR (%), 2015-2027
  • Figure 3.13 Global Aranesp Forecast: Revenue ($m), AGR (%), 2015-2027
  • Figure 3.14 Global Biosimilars Forecast: Revenue ($m), AGR (%), 2015-2027
  • Figure 3.15 Global Retacrit Forecast: Revenue ($m), AGR (%), 2015-2027
  • Figure 3.16 Global EPIAO Forecast: Revenue ($m), AGR (%), 2015-2027
  • Figure 3.17 Global Epoetin Alfa BS Forecast: Revenue ($m), AGR (%), 2015-2027
  • Figure 3.18 Global Espogen Forecast: Revenue ($m), AGR (%), 2015-2027
  • Figure 3.19 Global Erythropoietin Market by Application: Market Share (%), 2016
  • Figure 3.20 Global Erythropoietin Market by Application: Market Share (%), 2021
  • Figure 3.21 Global Erythropoietin Market by Application: Market Share (%), 2027
  • Figure 3.22 Global Anemia Forecast: Revenue ($m), AGR (%), 2015-2027
  • Figure 3.23 Global Kidney Disorders Forecast: Revenue ($m), AGR (%), 2015-2027
  • Figure 3.24 Global Others Forecast: Revenue ($m), AGR (%), 2015-2027
  • Figure 4.1 Global Erythropoietin API Manufacturing Forecast: Revenue ($m), AGR (%), 2015-2027
  • Figure 4.2 Global Erythropoietin API Manufacturing: Market Share (%), 2016
  • Figure 4.3 Global Erythropoietin API Manufacturing: Market Share (%), 2021
  • Figure 4.4 Global Erythropoietin API Manufacturing: Market Share (%), 2027
  • Figure 4.5 Global Contract Erythropoietin API Manufacturing Forecast: Revenue ($m), AGR (%), 2015-2027
  • Figure 4.6 Global In-House Erythropoietin API Manufacturing Forecast: Revenue ($m), AGR (%), 2015-2027
  • Figure 5.1 World Erythropoietin Market: Revenues ($m) by Region, 2015
  • Figure 5.2 World Erythropoietin Market: Revenues ($m) by Region, 2016
  • Figure 5.3 Global Erythropoietin Market Forecast: Revenue ($m), AGR (%), 2015-2027
  • Figure 5.4 World Erythropoietin Market: Market Shares (%) by Regional Market, 2016
  • Figure 5.5 World Erythropoietin Market: Market Shares (%) by Regional Market, 2021
  • Figure 5.6 World Erythropoietin Market: Market Shares (%) by Regional Market, 2027
  • Figure 6.1 North America Erythropoietin Market Forecast: Revenues ($m), AGR (%), 2015-2027
  • Figure 6.2 North America Erythropoietin Market: Market Shares (%) by Country, 2016
  • Figure 6.3 North America Erythropoietin Market: Market Shares (%) by Country, 2021
  • Figure 6.4 North America Erythropoietin Market: Market Shares (%) by Country, 2027
  • Figure 6.5 US Erythropoietin Market Forecast: Revenues ($m), AGR (%), 2015-2027
  • Figure 6.6 Canada Erythropoietin Market Forecast: Revenues ($m), AGR (%), 2015-2027
  • Figure 7.1 Europe Erythropoietin Market Forecast: Revenues ($m), AGR (%), 2015-2027
  • Figure 7.2 Europe Erythropoietin Market: Market Shares (%) by Country, 2016
  • Figure 7.3 Europe Erythropoietin Market: Market Shares (%) by Country, 2021
  • Figure 7.4 Europe Erythropoietin Market: Market Shares (%) by Country, 2027
  • Figure 7.5 Germany Erythropoietin Market Forecast: Revenues ($m), AGR (%), 2015-2027
  • Figure 7.6 France Erythropoietin Market Forecast: Revenues ($m), AGR (%), 2015-2027
  • Figure 7.7 U.K. Erythropoietin Market Forecast: Revenues ($m), AGR (%), 2015-2027
  • Figure 7.8 Italy Erythropoietin Market Forecast: Revenues ($m), AGR (%), 2015-2027
  • Figure 7.9 Spain Erythropoietin Market Forecast: Revenues ($m), AGR (%), 2015-2027
  • Figure 7.10 Rest of Europe Erythropoietin Market Forecast: Revenues ($m), AGR (%), 2015-2027
  • Figure 8.1 Asia Pacific Erythropoietin Market Forecast: Revenues ($m), AGR (%), 2015-2027
  • Figure 8.2 Asia Pacific Erythropoietin Market: Market Shares (%) by Country, 2016
  • Figure 8.3 Asia Pacific Erythropoietin Market: Market Shares (%) by Country, 2021
  • Figure 8.4 Asia Pacific Erythropoietin Market: Market Shares (%) by Country, 2027
  • Figure 8.5 China Erythropoietin Market Forecast: Revenues ($m), AGR (%), 2015-2027
  • Figure 8.6 Japan Erythropoietin Market Forecast: Revenues ($m), AGR (%), 2015-2027
  • Figure 8.7 India Erythropoietin Market Forecast: Revenues ($m), AGR (%), 2015-2027
  • Figure 8.8 Rest of Asia Pacific Erythropoietin Market Forecast: Revenues ($m), AGR (%), 2015-2027
  • Figure 9.1 Latin America Erythropoietin Market Forecast: Revenues ($m), AGR (%), 2015-2027
  • Figure 9.2 Latin America Erythropoietin Market: Market Shares (%) by Country, 2016
  • Figure 9.3 Latin America Erythropoietin Market: Market Shares (%) by Country, 2021
  • Figure 9.4 Latin America Erythropoietin Market: Market Shares (%) by Country, 2027
  • Figure 9.5 Brazil Erythropoietin Market Forecast: Revenues ($m), AGR (%), 2015-2027
  • Figure 9.6 Mexico Erythropoietin Market Forecast: Revenues ($m), AGR (%), 2015-2027
  • Figure 9.7 Rest of Latin America Erythropoietin Market Forecast: Revenues ($m), AGR (%), 2015-2027
  • Figure 10.1 Middle East and Africa Erythropoietin Market Forecast: Revenues ($m), AGR (%), 2015-2027
  • Figure 10.2 Middle East and Africa Erythropoietin Market: Market Shares (%) by Country, 2016
  • Figure 10.3 Middle East and Africa Erythropoietin Market: Market Shares (%) by Country, 2021
  • Figure 10.4 Middle East and Africa Erythropoietin Market: Market Shares (%) by Country, 2027
  • Figure 10.5 Saudi Arabia Erythropoietin Market Forecast: Revenues ($m), AGR (%), 2015-2027
  • Figure 10.6 South Africa Erythropoietin Market Forecast: Revenues ($m), AGR (%), 2015-2027
  • Figure 10.7 Rest of MEA Erythropoietin Market Forecast: Revenues ($m), AsGR (%), 2015-2027
  • Figure 11.1 Amgen, Inc.: Revenue ($m), AGR (%), 2011-2015
  • Figure 11.2 Johnson & Johnson: Revenue ($m), AGR (%), 2011-2015
  • Figure 11.3 Johnson & Johnson: Business Segment Revenue Share (%), 2015
  • Figure 11.4 Roche: Revenue ($m), AGR (%), 2011-2015
  • Figure 11.5 Roche: Business Segment Revenue Share (%), 2016
  • Figure 11.6 Biocon: Revenue ($m), AGR (%), 2012-2016
  • Figure 11.7 Biocon: Business Segment Revenue Share (%), 2016
  • Figure 11.8 3SBio: Revenue ($m), AGR (%), 2011-2015
  • Figure 11.9 3SBio: Business Segment Revenue Share (%), 2015
  • Figure 11.10 Pfizer, Inc.: Revenue ($m), AGR (%), 2011-2015
  • Figure 11.11 Pfizer, Inc.: Business Segment Revenue Share (%), 2015
  • Figure 11.12 Kyowa Hakko Kirin Co Ltd.: Revenue ($m), AGR (%), 2012-2016
  • Figure 11.13 Kyowa Hakko Kirin Co Ltd.: Pharmaceuticals Business Segment Revenue Share (%), 2015
  • Figure 11.14 LG Life Sciences Limited: Revenue ($m), AGR (%), 2011-2015
  • Figure 11.15 Novartis: Revenue ($m), AGR (%), 2012-2016
  • Figure 11.16 Novartis: Revenue, by Region, Share (%), 2016
  • Figure 12.1 Global Erythropoietin Market by Product Type: Market Share (%), 2016
  • Figure 12.2 Erythropoietin Market, By Region Share (%), 2016, 2021, 2027

Companies Listed

  • 3SBio Inc.
  • Accord Healthcare Limited
  • Actavis
  • Akebia Therapeutics
  • Amgen
  • Astellas Pharma Inc
  • AstraZeneca
  • Bio Sidus SA
  • Biocon Ltd
  • Casa Marzam
  • Casa Saba
  • Chugai Pharmaceutical
  • Claes-Göran Östenson
  • Corvidia Therapeutics
  • DaVita Inc
  • Dr. Reddy's Laboratories
  • FibroGen
  • First Shanghai Investments Limited
  • Fresenius Medical Care North America (FMCNA)
  • Galenica
  • Germans Trias i Pujol Hospital
  • GlaxoSmithKline
  • H. Lundbeck A/S
  • Hoffmann-La Roche
  • Hospira
  • Janssen Biotech
  • Japan Chemical Research Pharmaceuticals Co., Ltd.
  • Johnson & Johnson
  • Kissei pharmaceuticals
  • Kosin University Gospel Hospital
  • Kyowa Hakko Kirin Co Ltd
  • LG Life Sciences Limited
  • NADRO
  • NovaQuest Co-Investment Fund I, L.P.
  • Novartis Institutes for BioMedical Research (NIBR)
  • Novartis Pharmaceuticals
  • NOXXON Pharma AG
  • Pfizer
  • Proveedora de Medicamentos
  • RPG Life Sciences
  • Sandoz
  • Sirton Pharma
  • Stada
  • Stem Cell Therapeutics Corp.
  • Teva Pharmaceutical Industries Ltd.
  • UBI Pharma Inc.
  • Vifor Pharma

List of Organizations Mentioned in the Report

  • Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM)
  • Centers of Disease Control and Preventions
  • China's Ministry of Health (MOH)
  • Committee for Medicinal Products for Human Use (CHMP)
  • Department of Health & Family Welfare of Karnataka
  • Deutsches Ärzteblatt
  • EMA
  • European Commission (EC)
  • FDA
  • Indian Council of Medical Research (ICMR)
  • International Agency for Research on Cancer (IARC)
  • Ministry of Health, Malaysia
  • National Cancer Institute
  • National Center for Biotechnology Information
  • National Kidney Foundation
  • UK Nephrology - Renal Association
  • World Cancer Research Fund International
  • World Health Organizations
Back to Top